PURPOSE: To examine the organizational design features that were consistently associated in 2010 with high levels of patient enrollment onto National Cancer Institute (NCI) cancer treatment trials among the oncology practices and hospitals participating in the NCI Community Clinical Oncology Program (CCOP). METHODS: Fuzzy-set qualitative comparative analysis was used to identify the recipes (ie, combinations of organizational design features) that CCOPs used to achieve high levels of patient enrollment onto NCI treatment trials in 2010. Four organizational design features were examined: number of open treatment trials with at least one patient enrolled, number of newly diagnosed patients with cancer, number of CCOP-affiliated physicians, and number of CCOP-affiliated hospitals or practices where patient enrollment could occur. Data were obtained from NCI data systems and CCOP grant progress reports. RESULTS: Two recipes were consistently associated with high levels of patient enrollment onto NCI treatment trials in 2010: having many open treatment trials and many new patients with cancer, and having many open treatment trials and many affiliated hospitals or practices. Together, these recipes accounted for nearly two thirds of CCOP membership in the high-performance set in 2010. CONCLUSION: No single organizational design feature, by itself, was consistently associated with high levels of patient enrollment onto NCI treatment trials in 2010. Having a large menu of active treatment trials may be necessary to achieve high-patient enrollment performance, but this is not sufficient unless combined with either large patient volume or many participating sites.
PURPOSE: To examine the organizational design features that were consistently associated in 2010 with high levels of patient enrollment onto National Cancer Institute (NCI) cancer treatment trials among the oncology practices and hospitals participating in the NCI Community Clinical Oncology Program (CCOP). METHODS: Fuzzy-set qualitative comparative analysis was used to identify the recipes (ie, combinations of organizational design features) that CCOPs used to achieve high levels of patient enrollment onto NCI treatment trials in 2010. Four organizational design features were examined: number of open treatment trials with at least one patient enrolled, number of newly diagnosed patients with cancer, number of CCOP-affiliated physicians, and number of CCOP-affiliated hospitals or practices where patient enrollment could occur. Data were obtained from NCI data systems and CCOP grant progress reports. RESULTS: Two recipes were consistently associated with high levels of patient enrollment onto NCI treatment trials in 2010: having many open treatment trials and many new patients with cancer, and having many open treatment trials and many affiliated hospitals or practices. Together, these recipes accounted for nearly two thirds of CCOP membership in the high-performance set in 2010. CONCLUSION: No single organizational design feature, by itself, was consistently associated with high levels of patient enrollment onto NCI treatment trials in 2010. Having a large menu of active treatment trials may be necessary to achieve high-patient enrollment performance, but this is not sufficient unless combined with either large patient volume or many participating sites.
Authors: William R Carpenter; Bryan J Weiner; Arnold D Kaluzny; Marisa Elena Domino; Shoou-Yih Daniel Lee Journal: Med Care Date: 2006-07 Impact factor: 2.983
Authors: Lori M Minasian; William R Carpenter; Bryan J Weiner; Darrell E Anderson; Worta McCaskill-Stevens; Stefanie Nelson; Cynthia Whitman; Joseph Kelaghan; Ann M O'Mara; Arnold D Kaluzny Journal: Cancer Date: 2010-10-01 Impact factor: 6.860
Authors: A D Kaluzny; L M Lacey; R Warnecke; J P Morrissey; E Sondik; L Ford Journal: Cancer Epidemiol Biomarkers Prev Date: 1994 Apr-May Impact factor: 4.254
Authors: Lauren M Hamel; Louis A Penner; Terrance L Albrecht; Elisabeth Heath; Clement K Gwede; Susan Eggly Journal: Cancer Control Date: 2016-10 Impact factor: 3.302
Authors: Sara R Jacobs; Bryan J Weiner; Bryce B Reeve; Morris Weinberger; Lori M Minasian; Marjorie J Good Journal: Clin Trials Date: 2014-06-05 Impact factor: 2.486
Authors: Michael E Roth; Ann M O'Mara; Nita L Seibel; David S Dickens; Anne-Marie Langevin; Brad H Pollock; David R Freyer Journal: J Oncol Pract Date: 2016-03-29 Impact factor: 3.840
Authors: Howard A Zaren; Suresh Nair; Ronald S Go; Rebecca A Enos; Keith S Lanier; Michael A Thompson; Jinxiu Zhao; Deborah L Fleming; John C Leighton; Thomas E Gribbin; Donna M Bryant; Angela Carrigan; Jennifer C Corpening; Kimberly A Csapo; Eileen P Dimond; Christie Ellison; Maria M Gonzalez; Jodi L Harr; Kathy Wilkinson; Andrea M Denicoff Journal: J Oncol Pract Date: 2013-03 Impact factor: 3.840